The design and synthesis of nucleoside analogues has been a subject of great interest in the discovery of novel anticancer and antiviral agents owing to the fact that they can be involved in the disruption of nucleic acid biosynthesis and thus inhibit cellular division and viral replication.
[1] Additionally, they have been utilised for various gene silencing techniques as constituents of antisense oligonucleotides, small interfering RNAs (siRNAs) and microRNA-targeting oligonucleotides (anti-miRNAs). [2] In particular, conformationally restricted nucleosides such as "locked nucleic acids" (LNAs), whereby the sugar moiety of the nucleoside is locked in the bioactive C3'-endo (North) or C2'-endo (South) conformations, represent an interesting class of nucleoside inhibitor as they can show a dramatic improvement in enzymatic recognition, as well as enhancing base stacking and backbone pre-organization. [3] Most of these systems are locked by virtue of bridging groups on the furanose unit alone, but there are also examples whereby the nucleobase is directly involved in the conformational restriction of the nucleoside (so-called 'cyclonucleosides'). [4] In this respect, we have an interest in the synthesis and use of anomeric spironucleosides, whereby the anomeric carbon belongs to both the sugar moiety and the nucleobase (Figure 1 ). This fixes the nucleobase in a specific orientation around the N-glycosidic bond, imposing an altered flexibility on the sugar moiety. Spiro-functionalised nucleosides have gained considerable interest with the discovery of (+)-hydantocidin 1, a natural spironucleoside with potent herbicidal and plant growth regulatory activity.
[5] However, to the best of our knowledge, synthetic work in this field is limited, with the majority of anomeric spirocycles being hydantoines or diketopiperazines analogues, or simple pseudonucleosides with anchored purinic and pyrimidinic bases. [6] As part of an on-going programme within our laboratories on the synthesis of non-natural nucleic acids, [7] we aimed to prepare a library of spiro-fuctionalised nucleosides, containing a [1,2,3]-triazolyl moiety using a straightforward and highly stereoselective route. It was felt that this class of spironucleoside would make an interesting alternative to the [1,2,4]-triazolyl class of nucleoside whose biological activity is well known, owing to their resemblance to ribavirin 2. [8] We therefore evaluated our resulting [1,2,3]-triazolospironucleosides for their anti-HMV activity in vitro. 
Results and Discussion
As depicted in the retrosynthetic path (Scheme 1), the versatility of the synthetic strategy towards novel anomeric spironucleosides 3 lies in the strategic installation of azide and alkyne moieties on the D-psicofuranose derivative 4, followed by an intramolecular Huisgen 1, 3- Abstract: An efficient synthesis of spirocyclic triazolooxazine nucleosides is described. This was achieved by the conversion of -D-psicofuranose to the corresponding azido-derivative, followed by alkylation of the primary alcohol with a range of propargyl bromides -obtained via Sonogashira chemistry. The products of these reactions underwent 1,3-dipolar addition smoothly to generate the protected spirocyclic adducts. These were easily deprotected to give the corresponding ribose nucleosides. The library of compounds obtained was investigated for its antiviral activity, using MHV (Mouse Hepatitis Virus) as a model wherein derivative 3f showed the most promising activity and tolerability. The first part of the synthesis is shown in Scheme 2 and followed the general procedure described by Fuentes and co-workers. [10] This involved isomerisation of 1,2:4,5-di-O-isopropylidene-Dpsicopyranose 7 (easily prepared in a multigram scale using a straightforward three-step procedure from -D-fructopyranose [11] ) to its furanose form 6a using amberlyst acid resin in acetone. The remaining alcohol was then converted to the benzoate ester 6b with a satisfactory overall yield of 70%.
Scheme 2. Synthesis of the azido-ribose system.
The benzoate ester was then treated with azidotrimethylsilane in the presence of trimethylsilyl triflate in acetonitrile under stringently anhydrous conditions at 0°C for 5 min to provide the -azido-1-trimethylsilyl ether 8 as the sole anomer. The silyl group was then removed smoothly with a mixture of acetone, acetic acid and methanol, giving alcohol 5a in 98% yield.
The alkylation of alcohol 5a with a range of propargyl bromides was then undertaken using BEMP (2-tert-Butylimino-2-diethylamino-1,3-dimethylperhydro-1,3,2-diazaphosphorine) as base to give the crude propargylic ether intermediates. The 3-arylprop-2-ynyl partners for the O-alkylation were prepared from commercially available aryl iodides and propargyl alcohol using a two-step process involving Sonogashira coupling [12] followed by conversion of the resulting 3-arylprop-2-ynyl alcohols to their corresponding bromides under Appel conditions (see supporting information). The crude propargyl ether intermediates 9 then underwent efficient intramolecular 1,3-dipolar cycloaddition upon heating in toluene for 24h to give the novel protected anomeric spironucleoside library 10 (Table 1) . [13] Finally, deacylation of the spiroderivative 10, using a 7 N solution of ammonia in methanol, followed by hydrolysis of the isopropylidene group with acidic resin (Dowex ® 50W) gave straightforward access to anomeric spironucleosides 3 in good yield (Scheme 3). Scheme 3. Final deprotection steps to obtain novel anomeric spirocyclic system 3.
As proof of final structure and to gain an understanding of the conformation of these systems, an X-ray crystal structure of 3g was obtained from a thin (0.02 x 0.03 x 0.31 mm) singlecrystal. The structure in space group P2 1 has two independent molecules in the asymmetric unit, each having a disordered benzene ring occupying two distinct conformations (A and B) at ca. 60° different rotations about the aryl bond. In the upper 
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Overall Yield 3a : R = H; 56% 3b : R = Me; 47% 3c : R = Et; 51% 3d : R = 2-Napthyl; 50% 3e : R = Ph; 67 % 3f : R = 4-Cl-C 6 H 4 ; 63% 3g : R = 4-MeO-C 6 H 4 ; 52% 3h : R = 4-F-C 6 H 4 ; 80% 3i : R = 3-F-C 6 H 4 ; 74% 3j : R = 2-F-C 6 H 4 ; 73% 3k : R = n-Pentyl; 69% 3 molecule, conformation A is 92% occupied and B is 8% occupied, whilst in the lower molecule, the occupancies are reversed. Encouragingly, and considering the 'locked' nature of our nucleoside system, the crystal structure when overlaid with the [1,2,4]-triazolyl drug ribavirin showed remarkable similarities in conformation, particularly with respect to the ribose ring system (Figure 3 ). This prompted us to evaluate the antiviral activity of our nucleoside analogues and these studies are described below. 
Biological Evaluation
Coronaviruses are the largest and most complex RNA viruses known, encoding an unusually wide array of proteins that interact with or modify viral RNA. [14] Examples include Severe Acute Respiratory Syndrome (Sars), and Middle Eastern Respiratory Syndrome (Mers), which are amongst the most lethal viruses currently known. Coronaviruses are predicted to be sensitive to RNA-like drugs, [15] and some nucleosides, such as ribavirin, have anti-coronaviral activity. [16, 17] We therefore chose the model coronavirus Mouse hepatitis virus (MHV) as a proving ground for the novel nucleoside analogs described in this study for antiviral activity.
In order to test for antiviral effects, MHV was grown on cells that had been pre-treated with the experimental compounds at a concentration of 1 mM. The amount of MHV released from infected cells usually peaks at about 14 hours after infection. Two of the treatments, 3b and 3f reduced the amount of MHV that was released by about ten-fold (Fig. 4A) . MHV infection in 17Cl-1 cells normally results in formation of large multinucleate syncytia followed by detachment of cells from the culture flask. [18] The most effective experimental compound from the previous assay was screened for the ability to protect cells from MHV-induced cytopathology. 17Cl-1 cells were pretreated with 3f 3 hours before infection, and surviving cells were photographed 24 hours after infection. Treatment with 3f resulted in a dose-dependent reduction in both syncytium formation and detachment (Fig. 4B) . From these data it was concluded that 3f exerted a protective effect on treated cells at concentrations up to 2 mM. This also demonstrated that the apparent antiviral activity of 3f was not simply an artifact of cytotoxicity.
More detailed dose-response experiments were performed for four of the experimental compounds in order to better gauge their antiviral potential. Pretreatment with 2 mM of 3f produced the strongest antiviral effects, resulting in approximately one millionfold reduction of MHV growth (Fig. 4C) . Together, these results demonstrate that 3f had antiviral activity against the model coronavirus MHV.
The 17Cl-1 mouse lung fibroblast line supports high-titre MHV growth, and was therefore chosen for both toxicity and antiviral testing. The effects of treatment on cell viability were assessed by 4 MTT assay. [19] Cell viability was assessed after one day or three days. Of the compounds studied, the most promising were tested in this assay. 3d was the most cytotoxic, while 3b, 3f and 3k (included as a control) were better tolerated ( Figure 5 ). The concentration which produced a 50% reduction in cell viability in these assays was greater than 1 mM for each of the experimental compounds tested ( Table 2 ), demonstrating that the compounds are relatively non-toxic. A further experiment was performed in order to learn more about the mechanism of 3f antiviral activity by evolving drug resistance. MHV was serially passaged eight times on 17Cl-1 cells, which had been pre-treated with 1 mM 3f, a concentration that reproducibly reduced viral growth by about 90%. Previous work on antiviral compounds suggested that these conditions were appropriate for the selection of drug-resistant coronavirus within about five passages. [20] However, MHV grown in the presence of 3f consistently produced about 10% of the virus produced in untreated control cells, and did not develop resistance (data not shown). These results suggest that the mechanism of action of 3f is unclear, and that effects of 3f on the cell cannot be ruled out as a potential explanation of the antiviral effects.
In conclusion, a novel triazolospirocylcic nucleoside array was assembled efficiently through intramolecular 1,3-dipolar cycloaddition methodology, and allowed the identification of agents that showed promising antiviral activity towards MHVthe most promising of these being the 4-chlorophenyl derivative 3f. Further work is underway to establish the mechanism of action of this inhibitor.
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Entry for the Consequently, these systems were tested for their antiviral properties and several were shown to have promising activity against Mouse Hepatitis Virus. 
